Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Maintenance in Advanced/Relapsed NKTCL
NCT03630731Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Aug 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT03630731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630731.